Jaguar Health Inc

For the period ended Mar 31, 2025. Filed May 15, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 15, 2025

JAGX$0.44+7.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

March 31, · December 31,
(In thousands, except share and per share data) · 2025 · 2024
(unaudited)
Assets
Current assets:
Cash	$	5,690	$	8,002
Accounts receivable, net		1,223		1,527
Other receivable		166		120
Inventory		10,555		10,345
Prepaid expenses and other current assets		12,805		12,204
Total current assets		30,439		32,198
Property and equipment, net		452		464
Operating lease - right-of-use asset		1,211		936
Intangible assets, net		18,011		18,479
Other assets		1,347		1,348
Total assets	$	51,460	$	53,425
Liabilities, Redeemable preferred stock, and Stockholders' equity
Current liabilities:
Accounts payable	$	7,028	$	5,286
Accrued liabilities		2,101		1,911
Deferred revenue		170		170
Operating lease liability, current		273		299
Notes payable, net of discount (includes note designated at Fair Value Option amounting to $18.6 million as of March 31, 2025, and $11.9 million as of December 31, 2024, respectively)		18,636		12,038
Total current liabilities		28,208		19,704
Operating lease liability, net of current portion		998		686
Deferred revenue - long term		510		553
Notes payable, net of discount, net of current portion (includes notes designated at Fair Value Option amounting to $18.4 million as of March 31, 2025, and $21.7 million as of December 31, 2024, respectively)		18,429		23,503
Total liabilities		48,145		44,446
Commitments and contingencies (See Note 6)
Redeemable preferred stock: $0.0001 par value; 179 shares designated from 10,000,000 preferred stock authorized at March 31, 2025, and December 31, 2024; 99 shares issued and outstanding at March 31, 2025 and December 31, 2024		2,485		2,485
Stockholders' equity
Series G convertible preferred stock: $0.0001 par value; 137 shares designated from 10,000,000 preferred stock authorized at March 31, 2025, and December 31, 2024; zero shares issued and outstanding at March 31, 2025 and December 31, 2024		—		—
Series I convertible preferred stock: $0.0001 par value; 118 shares designated from 10,000,000 preferred stock authorized at March 31, 2025, and December 31, 2024; zero shares issued and outstanding at March 31, 2025 and December 31, 2024		—		—
Series K junior participating preferred stock: $0.0001 par value; 300,000 and 0 shares designated from 10,000,000 preferred stock authorized at March 31, 2025, and December 31, 2024, respectively; zero shares issued and outstanding at March 31, 2025 and December 31, 2024		—		—
Common stock - voting: $0.0001 par value, 298,000,000 shares authorized at March 31, 2025, and December 31, 2024; 674,047 and 10,420,964 issued and outstanding at March 31, 2025, and December 31, 2024, respectively		—		—
Common stock - non-voting: $0.0001 par value, 50,000,000 shares authorized at March 31, 2025, and December 31, 2024; 9 shares issued and outstanding at March 31, 2025, and December 31, 2024		—		—
Additional paid-in capital		359,428		354,234
Noncontrolling interest		(952)		(791)
Accumulated deficit		(356,946)		(346,482)
Accumulated other comprehensive loss		(700)		(467)
Total stockholders' equity		830		6,494
Total liabilities, redeemable preferred stock and stockholders' equity	$	51,460	$	53,425

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.